|
Report Date : |
14.02.2014 |
IDENTIFICATION DETAILS
|
Name : |
BIOTEQUE CORPORATION |
|
|
|
|
Registered Office : |
5FL.-6, No.23, Sec.1, Chang-An E. Rd.,
Taipei 104, R.O.C. |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
13.11.1991 |
|
|
|
|
Com. Reg. No.: |
86306206 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturer and sales of medical supplies |
|
|
|
|
No of Employees : |
About 380 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – december 01, 2013
|
Country Name |
Previous Rating (30.09.2013) |
Current Rating (01.12.2013) |
|
Taiwan |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
TAIWAN - ECONOMIC OVERVIEW
Taiwan has a dynamic capitalist
economy with gradually decreasing government guidance of investment and foreign
trade. Exports, led by electronics, machinery, and petrochemicals have provided
the primary impetus for economic development. This heavy dependence on exports
exposes the economy to fluctuations in world demand. In 2009, Taiwan's GDP
contracted 1.8%, due primarily to a 13.1% year-on-year decline in exports. In
2010 GDP grew 10.7%, as exports returned to the level of previous years, and in
2011, grew 4.0%. In 2012, however, growth fell to 1.3%, because of softening
global demand. Taiwan's diplomatic isolation, low birth rate, and rapidly aging
population are major long-term challenges. Free trade agreements have
proliferated in East Asia over the past several years, but except for the
landmark Economic Cooperation Framework Agreement (ECFA) signed with China in
June 2010, so far Taiwan has been excluded from this greater economic integration
in part because of its diplomatic status. Negotiations continue on such
follow-on components of ECFA regarding trade in goods and services. The MA
administration has said that the ECFA will serve as a stepping stone toward
trade pacts with other key trade partners, which Taiwan subsequently launched
with Singapore and New Zealand. Taiwan's Total Fertility rate of just over one
child per woman is among the lowest in the world, raising the prospect of
future labor shortages, falling domestic demand, and declining tax revenues.
Taiwan's population is aging quickly, with the number of people over 65
accounting for 11.2% of the island's total population as of 2012. The island
runs a large trade surplus largely because of its surplus with China, and its
foreign reserves are the world's fifth largest, behind China, Japan, Saudi
Arabia, and Russia. In 2006 China overtook the US to become Taiwan's
second-largest source of imports after Japan. China is also the island's number
one destination for foreign direct investment. Three financial memorandums of
understanding, covering banking, securities, and insurance, took effect in
mid-January 2010, opening the island to greater investments from the mainland's
financial firms and institutional investors, and providing new opportunities
for Taiwan financial firms to operate in China. In August 2012, Taiwan Central
Bank signed a memorandum of understanding on cross-Strait currency settlement
with its Chinese counterpart. The MOU allows for the direct settlement of
Chinese RMB and the New Taiwan dollar across the Strait, which could help
develop Taiwan into a local RMB hub. Closer economic links with the mainland
bring greater opportunities for the Taiwan economy, but also poses new
challenges as the island becomes more economically dependent on China while
political differences remain unresolved.
|
Source
: CIA |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
5FL.-6, No.23, Sec.1,
Chang-An E. Rd., Taipei 104, Taiwan, R.O.C. |
|
Supplied Address: |
|
|
Telephone Number: |
+886-2-2571-0269 |
|
Fax Number: |
|
|
E-mail: |
Notes: Subject’s exact name and address are as above.
|
Credit Opinion: |
|
|
Risk Analysis: |
Average creditworthiness |
|
Registered Name: |
|
|
Registered Address: |
5FL.-6, No.23, Sec.1, Chang-An E. Rd.,
Taipei 104, Taiwan, R.O.C. |
|
Date of Foundation: |
1991-11-13 |
|
Registration Number: |
86306206 |
|
Registry: |
Department of Commerce, Ministry of Economic Affairs,
R.O.C. |
|
Registered Capital: |
NTD 1,200,000,000 (USD 40,680,000) (As of 2014.02, 1 NTD = 0.0339 USD) |
|
Paid-up Capital: |
NTD 837,769,360 (USD 28,400,381) |
|
Legal Representatives: |
Zongli Cai |
|
Legal Form: |
|
|
Principal Activities: |
|
|
Staff: |
|
|
Listed at Stock Exchange: |
Yes TPO:4107 |
|
Date of Last Annual Return: |
Subject was incorporated
on 1991-11-13 with registered number 86306206
as Joint Stock Company in
Taiwan.
Change of Name
|
Former Chinese
Name |
邦拓生物科技股份有限公司 |
|
Current Chinese
Name |
邦特生物科技股份有限公司 |
|
Name |
Subscription
Shares |
|
Zongli Cai |
4,026,000 |
|
Mingzhong Li |
1,773,912 |
|
Bangyan Zhang |
1,054,144 |
|
Shiguang Lv |
1,851,456 |
|
Yixun Li |
1,648,893 |
|
Jinlong Lin |
215,973 |
|
Hailu Chen |
874,894 |
|
King Polytechnic Engineering Co., Ltd.) |
748,948 |
|
Qinyi Li |
446,049 |
The information above is that of subject’s major shareholders.
Shareholder Information:
|
Registered Name: |
King Polytechnic Engineering
Co., Ltd. |
|
Registered Address: |
5fl., No.210, Ruiguang Rd.,
Neihu Dist., Taipei 114, Taiwan, R.O.C. |
|
Date of Foundation: |
1982-8-3 |
|
Registration Number: |
05114306 |
|
Registry: |
Department of Commerce, Ministry
of Economic Affairs, R.O.C. |
|
Registered Capital: |
NTD 1,000,000,000 (USD 33,900,000) (As of 2014.2, 1 NTD = 0.0339
USD) |
|
Paid-up Capital: |
NTD 687,290,890 (USD 23,299,161) |
|
Legal Representatives: |
Zhenpan Hong |
|
Legal Form: |
Joint Stock Company |
|
Listed at Stock Exchange: |
No |
|
Date of Last Annual Return: |
2013-7-15 |
Branch
|
Branch Registered Number |
28971553 |
|
Branch Name |
Yilan Branch |
|
Branch Manager |
Yixun Li |
|
Branch Address |
No. 5, Ziqiang Road, Longde Lane, Suao Town, Yilan County, Taiwan |
|
Date of Incorporation |
2008-11-14 |
Factory
|
Name: |
Yilan Factory |
|
Address: |
No. 5, Ziqiang Road, Longde Lane, Suao Town, Yilan County,
Taiwan |
|
Date of Foundation: |
2000-12-7 |
|
Date of Registration: |
2001-11-6 |
|
Factory Registration Number: |
99620123 |
|
Factory Manager: |
Zongli Cai |
|
Status: |
In Production |
|
Date of Last Annual Return: |
2012-3-2 |
Core Management
Directors
|
1 |
|
|
Name |
Zongli Cai |
|
Position |
Board Chairman |
|
2 |
|
|
Name |
Mingzhong Li |
|
Position |
Deputy Chairman/Manager |
|
3 |
|
|
Name |
Bangyan Zhang |
|
Position |
Director |
|
4 |
|
|
Name |
Shiguang Lv |
|
Position |
Director |
|
5 |
|
|
Name |
Yixun Li |
|
Position |
Director |
|
6 |
|
|
Name |
Jinlong Lin |
|
Position |
Director |
|
7 |
|
|
Name |
Hailu Chen |
|
Position |
Director |
|
8 |
|
|
Name |
Zhenpan Hong |
|
Position |
Supervisor |
|
9 |
|
|
Name |
Qinyi Li |
|
Position |
Supervisor |
Personnel
Structure
|
Total Employees |
About 380
employees |
Offices & Factories
|
|
Headquarters |
|
Add |
5FL.-6, No.23, Sec.1, Chang-An E. Rd., Taipei 104, Taiwan, R.O.C. |
Production Information
l
Subject is a manufacturer of medical supplies
l
Subject has factory in Taiwan for production.
l
It is introduced that subject has obtained the
certification of GMP, ISO9001, ISO13485, CE0434 and FDA 510 (K), etc
Purchase Information
l
The registered activities of subject:
|
Business
Code |
Details
|
|
CF01011 |
|
|
F108031 |
|
|
F208031 |
|
|
ZZ99999 |
Besides licensed business, all other
business items those are not banned or restricted. |
l
Subject’s products are mainly made of TPU, Silicon,
PTFE, PFA, Nylon, etc
l
Subject purchases both at home and abroad.
Sales
Information
l
The subject is mainly engaged in sales of medical supplies.
l
Subject’s products are applied to nephrology,
urology, radiology, Cardiology, Respiratory Therapy, Critical Care, iv
administration therapy and molding parts, etc
l
Subject’s products are both sold in domestic and
overseas market and it is introduced that subject exports to over 40 countries
in America, Europe, Asia and Africa.
Major products sold
|
Type
|
Product |
|
Nephrology |
Hemodialysis Bloodine A.V. Fistula Needle Transducer Protector Hemodialysis
Catheter |
|
Vascular Access |
PTCA Balloon Dilatation Catheter Angiographic Catheter PTA Balloon Dilatation Catheter Sheath Introducer Guidewire High Pressure Connecting Tube |
|
Respiratory Care |
Closed Suction Catheter |
|
Urology |
Double-J Ureteral Stent Positioner |
|
Iv Administration Therapy |
PVC IV Bag PVC IV Bag (non-DEHP) IV Bag Accessories PVC Roll IV Infusion Set |
|
Medical Components |
For Bloodline For A.V. Fistula Needle |
|
Miscellaneous |
High-pressure Syringe Pressure Connecting Tube Insufflation Tubing Set Surgical Drainage Tube Drainage Bag Leg Urine Bag |
|
Savderm Wound Care |
Debridement Gel Dressings for Moderate to Heavy Exudates Dressings for None to Slight Exudates Antiseptic Dressings Skin and Scar Care Dressings Functional Dressings |
|
Comfort Care |
Surgical Tape and Dressing |
Import and export
right:
|
Import right |
Yes |
|
Export right |
Yes |
Purchase
Domestic Purchase
|
Payment Terms |
Proportion |
|
|
Raw materials, etc |
COD, Credit Sales, etc |
100% |
Foreign Purchase
|
Payment Terms |
Proportion |
|
|
Raw materials, etc |
CBD, etc |
100% |
Sales
Domestic Markets
|
Sales Terms |
Proportion |
|
|
Medical supplies |
CBD, etc |
100% |
Export
|
Sales Terms |
Proportion |
|
|
Medical supplies |
CBD, etc |
100% |
Unit: NTD/000
|
|
2012-12-31 |
2011-12-31 |
|
Assets |
|
|
|
Current Assets |
|
|
|
Cash and cash equivalents |
77,785.00 |
78,472.00 |
|
Available-for-sale financial assets
- current |
309,559.00 |
286,743.00 |
|
Notes receivable - net |
48,233.00 |
31,018.00 |
|
Accounts receivable - net |
111,921.00 |
112,892.00 |
|
Other financial assets - current |
2.00 |
3.00 |
|
Inventories |
116,280.00 |
105,221.00 |
|
Other current assets |
11,603.00 |
9,773.00 |
|
Current assets |
675,383.00 |
624,122.00 |
|
Funds and Investments |
|
|
|
Available-for-sale financial assets - non
current |
659.00 |
1,127.00 |
|
Long-term investments under
equity method |
262,571.00 |
266,243.00 |
|
Investments |
262,571.00 |
266,243.00 |
|
Other financial assets - uncurrent |
654.00 |
674.00 |
|
Funds and investments |
263,884.00 |
268,044.00 |
|
Fixed Assets |
|
|
|
Cost |
|
|
|
Land |
91,834.00 |
100,334.00 |
|
Buildings and structures |
398,521.00 |
396,041.00 |
|
Machinery and equipment |
456,223.00 |
438,724.00 |
|
Utilities equipment |
4,237.00 |
4,237.00 |
|
office equipment |
19,960.00 |
18,722.00 |
|
Other facilities |
71,440.00 |
57,709.00 |
|
Revaluation increment |
0.00 |
0.00 |
|
Cost and revaluation increment |
1,042,215.00 |
1,015,767.00 |
|
Accumulated depreciation |
-363,058.00 |
-298,346.00 |
|
Construction in process and prepayment for
equipments |
6,408.00 |
15,818.00 |
|
Fixed assets |
685,565.00 |
733,239.00 |
|
Intangible Assets |
|
|
|
Deferred pension costs |
278.00 |
0.00 |
|
Intangible assets |
278.00 |
0.00 |
|
OtherAssets |
|
|
|
Deferred charges |
1,326.00 |
2,832.00 |
|
Other assets |
1,326.00 |
2,832.00 |
|
Assets |
1,626,436.00 |
1,628,237.00 |
|
Liabilities and Stockholders' Equity |
|
|
|
Liabilities |
|
|
|
Current Liabilities |
|
|
|
Short-term borrowing |
0.00 |
0.00 |
|
Changes in the fair value of the
financial liability on profit and loss-flow |
0.00 |
0.00 |
|
Notes payable |
13,958.00 |
19,728.00 |
|
Accounts payable |
43,010.00 |
39,197.00 |
|
Income tax payable |
21,040.00 |
1,535.00 |
|
Accrued expenses |
48,623.00 |
48,384.00 |
|
Other payables |
4,450.00 |
3,912.00 |
|
Long-Term Liabilities -Current Portion |
26,400.00 |
32,650.00 |
|
Other current liabilities |
22,476.00 |
21,691.00 |
|
Current liabilities |
179,957.00 |
167,097.00 |
|
Long term Liabilities |
|
|
|
Long-term borrowings |
124,200.00 |
172,475.00 |
|
Long-term liabilities |
124,200.00 |
172,475.00 |
|
Reserves |
|
|
|
Other Liabilities |
|
|
|
Pension reserve / accrued pension
liability |
3,256.00 |
2,462.00 |
|
Guarantee deposits received |
0.00 |
10.00 |
|
Deferred income taxes |
35,411.00 |
36,289.00 |
|
Other liabilities - other |
0.00 |
8,941.00 |
|
Other liabilities |
38,667.00 |
47,702.00 |
|
Liabilities |
342,824.00 |
387,274.00 |
|
Stockholders' Equity |
|
|
|
Capital |
|
|
|
Common stock |
782,769.00 |
782,769.00 |
|
Capital Surplus |
|
|
|
Capital surplus - additional paid-in
capital |
83,003.00 |
83,003.00 |
|
Capital surplus |
83,003.00 |
83,003.00 |
|
Retained Earnings |
|
|
|
Legal reserve |
118,366.00 |
105,507.00 |
|
The special reserve |
43,229.00 |
53,270.00 |
|
Unappropriated retained earnings |
305,718.00 |
259,643.00 |
|
Retained earnings |
467,313.00 |
418,420.00 |
|
Stockholders' Equity and Other adjustment |
|
|
|
Cumulative translation adjustments |
-41,469.00 |
-31,816.00 |
|
Net loss not recognized as pension cost |
-528.00 |
0.00 |
|
Unrealized gains (losses) on financial
instruments |
-7,476.00 |
-11,413.00 |
|
Equity adjustments |
-49,473.00 |
-43,229.00 |
|
Stockholders‘ equity |
1,283,612.00 |
1,240,963.00 |
|
Number of Treasury Stock
Acquired by Parent Company and Subsidiaries (unit: Share) |
0.00 |
0.00 |
|
Equivalent Shares of
Outstandings of Advance Receipts for Common Stock (Unit: Share) |
0.00 |
0.00 |
Unit: NTD/000
|
|
2012 |
2011 |
|
Sales |
845,784.00 |
759,956.00 |
|
Return inward |
3,650.00 |
519.00 |
|
Sales discounts and allowances |
0.00 |
0.00 |
|
Sales |
842,134.00 |
759,437.00 |
|
Operating income |
842,134.00 |
759,437.00 |
|
Cost of sales |
547,709.00 |
519,937.00 |
|
Operating costs |
547,709.00 |
519,937.00 |
|
Gross profit (loss) from operations |
294,425.00 |
239,500.00 |
|
Selling expense |
49,501.00 |
49,250.00 |
|
General and administrative expenses |
43,300.00 |
36,876.00 |
|
Research and development expenses |
45,362.00 |
47,288.00 |
|
Operating expenses |
138,163.00 |
133,414.00 |
|
Operating income (loss) |
156,262.00 |
106,086.00 |
|
Non-Operating Income |
|
|
|
Interest income |
233.00 |
101.00 |
|
Income from long-term equity investments
under the equity method |
6,086.00 |
898.00 |
|
Investment income |
6,086.00 |
898.00 |
|
Income gain |
0.00 |
0.00 |
|
Gains on disposal of fixed assets |
11,600.00 |
0.00 |
|
Foreign exchange gains |
688.00 |
5,131.00 |
|
Financial assets evaluation |
2,650.00 |
1,970.00 |
|
Financial liability evaluation |
0.00 |
509.00 |
|
Miscellaneous income |
23,416.00 |
28,196.00 |
|
Non-operating revenues and gains |
44,673.00 |
36,805.00 |
|
Non-Operating Expenses |
|
|
|
Interest expense |
2,952.00 |
3,460.00 |
|
Investment losses under equity method |
0.00 |
0.00 |
|
Investment losses |
0.00 |
0.00 |
|
Loss on disposal of fixed assets |
4,059.00 |
0.00 |
|
Loss on exchange |
0.00 |
0.00 |
|
Loss on valuation of financial asset |
0.00 |
0.00 |
|
Financial liability loss evaluation |
0.00 |
0.00 |
|
Miscellaneous disbursements |
50.00 |
0.00 |
|
Non-operating expenses and losses |
7,061.00 |
3,460.00 |
|
Income from continuing operations before
income tax |
193,874.00 |
139,431.00 |
|
Income tax expense (benefit) |
27,566.00 |
10,834.00 |
|
Income from continuing operations |
166,308.00 |
128,597.00 |
|
Net income (loss) |
166,308.00 |
128,597.00 |
|
Primary Earnings per Share |
|
|
|
Primary earnings per share |
2.12 |
1.64 |
|
Diluted earnings per share |
|
|
|
Diluted earnings per share |
2.11 |
1.63 |
Subject declined to disclose its bank details; from other source we
cannot obtain the relevant information, either.
Mortgage
|
Case Type: |
Chattel Mortgage |
|
Certificate No.: |
097823 |
|
Debtor Name: |
Bioteque Corporation |
|
Document Number: |
09830461530 |
|
Date of Registration: |
2009/7/27 |
Lawsuit
Up to date of reporting, no existing or latent
litigation of the subject has been found.
|
Department |
Sales department |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 62.27 |
|
|
1 |
Rs. 103.46 |
|
Euro |
1 |
Rs. 84.87 |
INFORMATION DETAILS
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.